home / stock / imrn / imrn quote
Last: | $2.01 |
---|---|
Change Percent: | -1.98% |
Open: | $2.06 |
Close: | $2.01 |
High: | $2.1839 |
Low: | $1.93 |
Volume: | 17,876 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.01 | $2.06 | $2.01 | $2.1839 | $1.93 | 17,876 | 07-05-2024 |
$2.02 | $2.09 | $2.02 | $2.1982 | $1.9607 | 18,714 | 07-04-2024 |
$2.02 | $2.09 | $2.02 | $2.1982 | $1.9607 | 18,714 | 07-03-2024 |
$2.161 | $2.24 | $2.161 | $2.24 | $2.12 | 2,887 | 07-02-2024 |
$2.2595 | $2.4 | $2.2595 | $2.4 | $2.0501 | 14,684 | 07-01-2024 |
$2.42 | $2.47 | $2.42 | $2.4918 | $2.4 | 6,843 | 06-28-2024 |
$2.4978 | $2.545 | $2.4978 | $2.5507 | $2.4978 | 5,872 | 06-27-2024 |
$2.52 | $2.5001 | $2.52 | $2.53 | $2.5001 | 1,725 | 06-26-2024 |
$2.5 | $2.43 | $2.5 | $2.54 | $2.43 | 11,891 | 06-25-2024 |
$2.5 | $2.21 | $2.5 | $2.56 | $2.15 | 33,953 | 06-24-2024 |
$2.12 | $2.11 | $2.12 | $2.2399 | $2.1 | 15,183 | 06-21-2024 |
$2.15 | $2.1101 | $2.15 | $2.1878 | $2.1101 | 3,401 | 06-20-2024 |
$2.12 | $2.11 | $2.12 | $2.175 | $2.1 | 2,889 | 06-19-2024 |
$2.12 | $2.11 | $2.12 | $2.175 | $2.1 | 2,889 | 06-18-2024 |
$2.1 | $2.1878 | $2.1 | $2.22 | $2.1 | 7,735 | 06-17-2024 |
$2.17 | $2.1801 | $2.17 | $2.23 | $2.16 | 4,818 | 06-14-2024 |
$2.2399 | $2.18 | $2.2399 | $2.2399 | $2.18 | 3,729 | 06-13-2024 |
$2.24 | $2.18 | $2.24 | $2.24 | $2.18 | 3,738 | 06-12-2024 |
$2.26 | $0 | $2.26 | $0 | $0 | 307 | 06-11-2024 |
$2.26 | $2.22 | $2.26 | $2.3 | $2.22 | 6,208 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug A...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed a...
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky H...